Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.

Askoxylakis V, Ferraro GB, Badeaux M, Kodack DP, Kirst I, Shankaraiah RC, Wong CSF, Duda DG, Fukumura D, Jain RK.

NPJ Breast Cancer. 2019 Jan 15;5:4. doi: 10.1038/s41523-018-0100-8. eCollection 2019.

2.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, Benes CH.

Cell Rep. 2017 Dec 12;21(11):3298-3309. doi: 10.1016/j.celrep.2017.11.051.

3.

Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?

Askoxylakis V, Kodack DP, Ferraro GB, Jain RK.

Breast Cancer Res Treat. 2017 Sep;165(2):467-468. doi: 10.1007/s10549-017-4351-0. Epub 2017 Jun 22. No abstract available.

PMID:
28643019
4.

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.

Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK.

Sci Transl Med. 2017 May 24;9(391). pii: eaal4682. doi: 10.1126/scitranslmed.aal4682. Erratum in: Sci Transl Med. 2019 Jan 30;11(477):.

5.

Closing the gap: astrocytes and brain metastasis.

Ferraro GB, Kodack DP, Askoxylakis V, Jain RK.

Cell Res. 2016 Sep;26(9):973-4. doi: 10.1038/cr.2016.96. Epub 2016 Aug 12.

6.

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.

Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig MK, Brachtel E, Duda DG, Huang P, Fukumura D, Engelman JA, Jain RK.

J Natl Cancer Inst. 2015 Nov 7;108(2). pii: djv313. doi: 10.1093/jnci/djv313. Print 2016 Feb.

7.

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T.

Cancer Cell. 2015 Jul 13;28(1):70-81. doi: 10.1016/j.ccell.2015.05.010. Epub 2015 Jul 2.

8.

Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.

Ager EI, Kozin SV, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V, Huang Y, Goel S, Snuderl M, Muzikansky A, Finkelstein DM, Dransfield DT, Devy L, Boucher Y, Fukumura D, Jain RK.

J Natl Cancer Inst. 2015 Feb 20;107(4). pii: djv017. doi: 10.1093/jnci/djv017. Print 2015 Apr.

9.

Emerging strategies for treating brain metastases from breast cancer.

Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D, Jain RK.

Cancer Cell. 2015 Feb 9;27(2):163-75. doi: 10.1016/j.ccell.2015.01.001. Review.

10.

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA.

Cancer Discov. 2014 Jan;4(1):42-52. doi: 10.1158/2159-8290.CD-13-0315. Epub 2013 Oct 25.

11.

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.

Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, Tannous BA, Eichler AF, Fukumura D, Engelman JA, Jain RK.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3119-27. doi: 10.1073/pnas.1216078109. Epub 2012 Oct 15.

12.

Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing.

Tassi E, McDonnell K, Gibby KA, Tilan JU, Kim SE, Kodack DP, Schmidt MO, Sharif GM, Wilcox CS, Welch WJ, Gallicano GI, Johnson MD, Riegel AT, Wellstein A.

Am J Pathol. 2011 Nov;179(5):2220-32. doi: 10.1016/j.ajpath.2011.07.043. Epub 2011 Sep 21.

13.

The biology of brain metastases-translation to new therapies.

Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK.

Nat Rev Clin Oncol. 2011 Jun;8(6):344-56. doi: 10.1038/nrclinonc.2011.58. Epub 2011 Apr 12. Review.

14.

Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.

Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A.

Oncogene. 2009 Sep 17;28(37):3296-306. doi: 10.1038/onc.2009.184. Epub 2009 Jul 27.

15.

Noninvasive tracking of cardiac embryonic stem cells in vivo using magnetic resonance imaging techniques.

Ebert SN, Taylor DG, Nguyen HL, Kodack DP, Beyers RJ, Xu Y, Yang Z, French BA.

Stem Cells. 2007 Nov;25(11):2936-44. Epub 2007 Aug 9.

16.

Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon.

Tassi E, Henke RT, Bowden ET, Swift MR, Kodack DP, Kuo AH, Maitra A, Wellstein A.

Cancer Res. 2006 Jan 15;66(2):1191-8.

Supplemental Content

Loading ...
Support Center